HepaStem

Promethera Biosciences to Present New NASH Data at Two International Scientific and Partnering Conferences in April

Poster at EASL Annual Congress 2018 Confirms HepaStem’s Anti-inflammatory Effect and Potential to Reduce Fibrosis in a Proven NASH Model

Mont-Saint-Guibert, Belgium, April 5, 2018 – Promethera Biosciences SA, a global innovator in cell-based medicines and liver diseases, today announced that the Company will participate in two upcoming scientific and partnering conferences in Europe and the US.

Sign Up